Long-term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Adult Participants With Generalized Myasthenia Gravis: Final Results of the ADAPT-SC+ Study (P9-9.002)

Ratna Bhavaraju-Sanka; Carlo Antozzi; Jan De Bleecker; Wan-Yi Huang; Rosa Jimenez; Fien Verhamme; Li Liu; Denis Korobko; Andreas Meisel; Kimiaki Utsugisawa; Tuan Vu; Heinz Wiendl; James Howard

doi:10.1212/wnl.0000000000216404

June 9, 2026Neurology

Long-term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Adult Participants With Generalized Myasthenia Gravis: Final Results of the ADAPT-SC+ Study (P9-9.002)

View Full Paper

Ask AI

Bookmark

Share

Key Points

Evaluate the long-term safety and efficacy of subcutaneous efgartigimod PH20 in adults with generalized myasthenia gravis.
Participants received subcutaneous efgartigimod PH20 coformulated with recombinant human hyaluronidase PH20.
Long-term follow-up was conducted to assess both safety and efficacy measures.
Evaluated participants were diagnosed with generalized myasthenia gravis.
Demonstrated sustained clinical improvement in participants over the study duration.
Showed favorable safety profile with minimal adverse effects reported during the follow-up.
Efgartigimod PH20 provided enhanced control of symptoms associated with generalized myasthenia gravis.

Implication

Evaluates efficacy and safety of efgartigimod in adults with generalized myasthenia gravis, suggesting potential benefits over time.

Abstract

ADAPT-SC+ evaluated long-term safety and efficacy of subcutaneous (SC) efgartigimod PH20 (coformulated with recombinant human hyaluronidase PH20) in participants with generalized myasthenia gravis (gMG).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bhavaraju-Sanka et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf36efaef96ed7f055deb https://doi.org/10.1212/wnl.0000000000216404

View Full Paper

Ask AI

Bookmark

Share

Long-term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Adult Participants With Generalized Myasthenia Gravis: Final Results of the ADAPT-SC+ Study (P9-9.002)

Key Points

Implication

Abstract

Discussion

Cite This Study

Long-term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Adult Participants With Generalized Myasthenia Gravis: Final Results of the ADAPT-SC+ Study (P9-9.002)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading